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Abstract
Objective: Cushing’s syndrome (CS) is associated with high cardiovascular risk. White matter lesions (WML) are common on
brain magnetic resonance imaging (MRI) in patients with increased cardiovascular risk.
Q1
Aim: To investigate the relationship between cardiovascular risk, WML, neuropsychological performance and brain
volume in CS.
Design/methods: Thirty-eight patients with CS (23 in remission, 15 active) and 38 controls sex-, age- and education-level
matched underwent a neuropsychological and clinical evaluation, blood and urine tests and 3Tesla brain MRI. WML were
analysed with the Scheltens scale. Ten-year cardiovascular risk (10CVR) and vascular age (VA) were calculated according to an
algorithm based on the Framingham heart study.
Results: Patients in remission had a higher degree of WML than controls and active patients (P!0.001 and PZ0.008
respectively), which did not correlate with cognitive performance in any group. WML severity positively correlated with
diastolic blood pressure (rZ0.659, PZ0.001) and duration of hypertension (rZ0.478, PZ0.021) in patients in remission.Both
patient groups (active and in remission) had higher 10CVR (PZ0.030, PZ0.041) and VA than controls (PZ0.013, PZ0.039).
Neither the 10CVR nor the VA correlated with WML, although both negatively correlated with cognitive function and brain
volume in patients in remission (P!0.05).Total brain volume and grey matter volume in both CS patient groups were reduced
compared to controls (total volume: active PZ0.006, in remission PZ0.012; grey matter: active PZ0.001, in remission
PZ0.003), with no differences in white matter volume between groups.
Conclusions: Patients in remission of Cushing’s syndrome (but not active patients) havemore severe white matter lesions than
controls, positively correlated with diastolic pressure and duration of hypertension. Ten-year cardiovascular risk and vascular
age appear to be negatively correlated with the cognitive function and brain volume in patients in remission of Cushing’s
syndrome.
European Journal of
Endocrinology
(2015) 173, 1–12
Introduction
Cushing’s syndrome (CS) is a rare disease due to a chronic
glucocorticoid excess. When endogenous, the most
common cause is a pituitary adenoma and, less frequently,
an adrenal or ectopic tumour (1). CS is associated with
severe morbidities and increased mortality, due to
systemic complications, that may persist after cure.
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These include central obesity, increased fat mass, reduced
bone and lean body mass, excessive fatigue, skin lesions
(purple striae, easy bruising, ulceration), hirsutism, hypo-
gonadism, hypertension, insulin resistance and/or dia-
betes mellitus, dyslipidemia, prothrombotic state, vascular
disease, atherosclerosis, depression, anxiety, cognitive
decline and impaired health-related quality of life (1, 2,
3, 4, 5, 6). Available treatments include surgery (pituitary
adenomectomy, adrenalectomy or excision of the ectopic
source of the adrenocorticotrophic hormone (ACTH)),
irradiation and cortisol-lowering drugs (7, 8).
Glucocorticoids can be neurotoxic to the brain by
modifying both neuronal structure and neurotrans-
mission (3). This can impair adult neurogenesis, lead
to region-specific alterations in dendrite and spine
morphology (i.e., reducing dendritic length and branch-
ing morphology), impair hippocampal long-term
potentiation and synaptic plasticity and also imply in
appropriate functional responses after a brief stress
exposure (9, 10). Reduced brain volume, both general
and specifically in the cerebellum or the hippocampus,
has been described in CS (11, 12, 13, 14, 15). Patients also
present neuropsychological alterations, mainly involving
memory. Moreover impairment in executive functions,
attention, visuoconstructive functions, language, infor-
mation processing speed and motor functions are also
present in these patients, although less consistently (10,
11, 13, 14, 16, 17). Because some brain and neuropsycho-
logical alterations are still present after biochemical cure,
it is suggested that the consequences of cortisol excess on
the brain are not completely reversible (3, 18, 19).
It is well known that suffering or having suffered CS
determines a higher cardiovascular risk (20, 21). Cardio-
vascular risk has consistently been linked to cognitive
impairments and brain white matter lesions (WML) (22).
WML (also known as leukoaraiosis) are evidenced on brain
MRI as hyperintensities on T2 or FLAIR images and usually
correspond to myelin loss and mild gliosis in brain areas
(23). In both aging and dementia, immunohistochemistry
on WML has revealed activated microglia, clasmatoden-
dritic astrocytosis, oligodendroglia apoptosis and upregu-
lated markers of hypoxia (24). They are supposed to have
an ischemic origin, due to the obstruction of small cerebral
vessels, which lead to acute or chronic ischaemia (25).
These WML are a common finding in patients with high
cardiovascular risk, like in hypertension, hypercholester-
olemia or diabetes, although they are also common in the
elderly, increasing with age (26). WML have important
clinical implications, as they have been related to poor
cognition, mainly in tests associated to executive
functioning but also with information processing speed,
memory, attention and psychomotor speed (23, 25).
Furthermore, they have also been related to an increased
risk of dementia, stroke and death (22). These lesions are
not static and may worsen over time, increasing in
number and volume. Baseline severity is perhaps the
most consistent predictor of progression, although other
reported factors are female sex and high blood pressure.
WML progression has also been associated with cognitive
decline (25, 27).
Patients with CS have increased cardiovascular risk
and therefore may be prone to develop WML. Reduced
integrity of brain white matter has been reported in CS,
indicating axon impairment (28, 29). This has been
established using diffusion tension imaging, a non-
invasive neuroimaging technique that assesses the motion
of water molecules along and across neuronal axons (28).
A specific software is needed to perform this kind of
analysis. In contrast, WML are characterized by macro-
scopic lesions, which can be seen and evaluated directly
on MRI by physicians in their clinical practice. Therefore,
the aim of this study was to investigate the relationship
between cardiovascular risk and WML, neuropsychologi-
cal performance and brain volume in CS. Our hypothesis
was that cardiovascular risk would have a role on WML
and that patients with CS (both active and in remission)
would have more WML than controls. Furthermore, both
cardiovascular risk andWMLwould be related to cognitive
deficits and decreased brain volume.
Methods
Patients
The study included 38 patients with CS (23 in remission,
15 active) routinely followed in our hospital and 38
controls matched for sex, age and years of education
(G3 years). Initially, 59 patients were approached; five
were not right-handed and were excluded. From the 54
remaining patients, five declined to participate (citing
lack of time or interest), nine had claustrophobia and
could not undergo an MRI and two had medical
incompatibilities for the MRI. Controls were recruited
from the blood donor’s center of the hospital and also
from other current studies. A matched control was
identified and recruited for each patient. Initially, 63
controls were invited to participate in the study; seven
were not right-handed and were excluded. From the
remaining controls, eight declined to participate (citing
lack of time or interest), nine were excluded as they could
EJE 150600—18/9/2015—13:12—MURUGANM—541870—XML StyleD – pp. 1–12
E
u
ro
p
e
an
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study A Santos and others CV risk and white matter
lesions in CS
173 :6 2
www.eje-online.org
Proof Only
not undergo an MRI due to claustrophobia and one was
excluded due to exogenous chronic glucocorticoid
exposure. The study was approved by the hospital’s ethics
committee, and all patients and controls signed an
informed consent before they were enrolled in the study.
Exclusion criteria for patients with CS were above age
65 years and had a growth hormone (GH) deficiency,
known prior cerebrovascular disease, severe neurological
or psychiatric illness and history of drug or alcohol abuse.
For controls, endocrine disease and glucocorticoid
exposure were additional exclusion criteria. Only right-
handed patients with CS and controls were included
(Edinburgh Handedness Inventory O80) (30).
Patients were considered biochemically cured of CS
after surgery if adrenal insufficiency was demonstrated
or if morning cortisol suppression (!50 nmol/l) was
observed after 1 mg dexamethasone overnight (16) and if
repeated 24-h urinary-free cortisol measures were normal
(!280 nmol/l). Patients who did not fulfil these criteria
were considered to have active CS.
Clinical interview, neuropsychological assessment
and biochemistry
Both patients and controls underwent a complete clinical
interview, which included demographic data, clinical
history, family history, any current treatments and an
assessment of blood pressure, height, weight and waist
circumference. The clinical interview for patients with CS
also included details on disease history, with a review of
clinical files.
Patients and controls also underwent a neuropsycho-
logical battery of tests. Tests evaluating functions that
have been related to WML in the literature (23, 25) were
selected, including Memory: Rey-Osterrieth Complex
Figure (31) and Rey Auditory Verbal-Learning Test (32);
Attention: Digit Span Forward (33) and Continuous
Performance Test II (34); Executive function: Trail Making
Test B (35), FAS (36), Animals (37), Wisconsin Card Sorting
Test (38) and Digit Span Backwards (33); Information
processing speed: Symbol Digit Modalities Test (39),
Wisconsin Card Sorting Test (mean time) (38) and
Continuous Performance Test – II (hit reaction time);
Motor functions: Grooved Pegboard (40) and Trail Making
Test A (35). A further description of the tests can be found
in Supplementary Table 1, see section on supplementary
data given at the end of this article. Individual test scores
were converted into Z-scores. In addition, Z-scores where
higher scores were related to a poorer performance
were inverted to guarantee that all scores were equivalent.
A Z-score of each cognitive domain was calculated, as the
mean of all Z-scores of the tests selected for a particular
cognitive function. Specifically, the cognitive domains
included the following scores: Memory: Rey-Osterrieth
Complex Figure (immediate and delayed recall) and Rey
Auditory Verbal-Learning Test (Rey 5 and Recognition A);
Attention: Digit Span Forward (total score) and Continu-
ous Performance Test II (omissions); Executive function:
Trail Making Test B (total time), FAS (total score), Animals
(total score), Wisconsin Card Sorting Test (perseverative
errors) and Digit Span Backwards (total score); Infor-
mation processing speed: Symbol Digit Modalities Test
(total score), Wisconsin Card Sorting Test (mean time) and
Continuous Performance Test II (hit reaction time); Motor
functions: Grooved Pegboard (total time for both domi-
nant and non-dominant hand) and Trail Making Test A
(total time) (41, 42).
Two questionnaires to assess depression (Beck
Depression Inventory II (BDI-II)) and anxiety (State Trait
Anxiety Inventory (STAI), which assesses both state and
trait anxiety) were also included in the study protocol.
To rule out an intra-examiner effect, all assessments were
performed by one neuropsychologist (A Santos).
Participants also had blood and urine tests. Urinary
free cortisol was determined from a 24-h collection using
a commercial radioimmunoassay. To assess cholesterol,
triglycerides and glucose from blood samples, standard
assay determinations were performed.
Magnetic resonance imaging
All participants underwent three Tesla magnetic reso-
nance imaging (MRI) of the whole brain. MRI was
obtained using a 3-Tesla Philips Achieva facility (SoftwareQ2
version 2.1.3.2) and a dedicated acquisition protocol:
3DMPRAGE whole brain sequence (repetition timeZ
6.7 ms; echo timeZ3.1 ms, 170 slices; voxel sizeZ1!1!
1.2; field of viewZ256!256!204) and FLAIR (repetition
timeZ8000 ms; echo timeZ332 ms; voxel sizeZ1.1!
1.1!0.6; field of viewZ250!250!250). The complete
acquisition protocol lasted approximately 45 min. FLAIR
images were analysed by two blinded neuroradiologists,
who scored the degree of WML according to the
semiquantitative rating scale described by Scheltens
(Scheltens scale) (43).
The Scheltens scale can range from 0 to 84 in which a
higher score indicates a higher degree ofWML. The score is
the sum of four subscores rated in a semiquantitave way.
It includes white matter hyperintensities in the periven-
tricular area (score: 0–6), the cerebral lobes (score: 0–24),
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the basal ganglia (score 0–30) and the infratentorial area
(score 0–30). Scores depend on both the presence of
lesions in different areas and the size of the lesion.
Furthermore, the routine MRI reports prepared by the
radiologists before using the Scheltens scale were collected
from the clinical files of patients and controls to analyse
in how many the presence of WML had already been
registered. This information was categorized in a dichoto-
mic way (detecting WML: yes/no).
Additionally, structural T1 MRIs were processed at
the Port d’Informacio´ Cientı´fica (PIC) of the Universitat
Autonoma de Barcelona. Whole brain, grey matter and
whitematter volumes weremeasured using FreeSurfer v5.3
Software. These volumes were normalised to the estimatedQ2
intracranial volume (eTIV) of each individual, as pre-
viously described (14).
Cardiovascular risk evaluation
Ten-year cardiovascular risk and vascular age were
calculated with a sex-specific multivariable risk factor
algorithm, which includes sex, age, systolic blood
pressure, smoking, diabetes, HDL and total cholesterol,
based on the Framingham heart study data (44). This
algorithm was developed using the longitudinal data of
Q7
8491 patients. The algorithm provides two scores: a
percent risk of suffering a cardiovascular event over the
next 10 years (10-year cardiovascular risk) and a further
Q8
quantification of this risk in the form of vascular age/heart
age (vascular age).
Statistical analysis
Statistical analysis was performed using IBM SPSS 21
software (SPSS, Inc.). Normal distribution was analysed
using the Kolmogorov-Smirnov test. ANOVA followed by a
post hoc analysis using Bonferroni was used for compari-
sons between the three groups (controls, active patients
and patients in remission). For non-normal data (10-year
cardiovascular risk, Scheltens score, Beck depression score
and triglyceride level), the Kruskal-Wallis test was used,
and the post hoc analysis was performed with a Mann
Whitney U test. Student’s t-test or Mann Whitney U test
for non-parametric variables were used when comparing
two groups. c2 was used to compare categorical variables.
Correlations were assessed using the Pearson coefficient or
the Sperman’s r for non-parametric variables. Differences
were considered significant when P!0.05.
Results
Demographic and clinical characteristics of patients and
controls are shown in Table 1. There were no differences
between groups for age, sex and educational level, as
expected due to prior matching.
Cardiovascular risk
The first analysis was devoted to cardiovascular risk.
Regarding the 10-year cardiovascular risk,both CS patient
groups (active and in remission) had a higher risk of
suffering a cardiovascular event during the next 10 years
Table 1 Clinical and demographic characteristics of patients (CS, active and in remission) and controls.
CS
Controls (nZ38)Active (nZ15) In remission (nZ23)
Age 44.3G9.3 42.9G10.6 42.7G10.3
Sex (female/male) 13/2 19/4 32/6
Years of education 13.7G2.7 13.2G3.3 13.7G3.3
Origin of CS (pituitary/adrenal/ectopic/AIMAH†) 10/3/1/1 20/3/0/0 –
Surgery (transsphenoidal/adrenal) 1/0 20/3 –
Radiotherapy – 5 –
Cortisol lowering medication (metyrapone/ketokonazole/
cabergoline/losartan)
4/7/1/1 – –
Hydrocortisone replacement – 8 –
Waist circumference (cm) 98.0G11.7* 93.1G14.8* 82.2G11.3
Total cholesterol (mmol/l) 5.2G0.7 5.2G1.0 5.1G0.9
Triglycerides (mmol/l) 1.0 (0.6–2.2)* 1.2 (0.6–3.9)* 0.7 (0.5–2.4)
Systolic blood pressure (mm/Hg) 132.0G21.7* 131.2G21.3* 112.8G15.9
Diastolic blood pressure (mm/Hg) 84.0G15.6* 82.3G10.7* 69.9G11.2
Glucose (mmol/l) 4.9G0.54 4.9G0.51 4.8G0.54
*Significant differences between patients and controls (P!0.05). All values are expressed as meanGS.D., except for triglycerides, expressed as median
and range.
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than controls (PZ0.037 and PZ0.044 respectively). More
specifically, active patients had a 8.1% risk, followed by
patients in remission (7.4% risk) and controls (3.9% risk).
Regarding vascular age, both patient groups had a
higher vascular age than controls (56.1G16.8 years in
active patients with CS, PZ0.013; 52.5G19.8 years
in patients in remission, PZ0.039; vs 42.1G11.9 years in
controls). This was remarkable, as the sample was initially
matched for age (mean between 42.7 and 44.3 years).
In fact, both patient groups (but not controls) had an
increased mean vascular age compared to their current
age (active CS 11.8 years more, PZ0.005; CS in remission
9.6 years more, PZ0.002).
Regarding specific parameters associated with cardio-
vascular risk, patients with CS (both in remission and
active) had a greater waist circumference (PZ0.005,
P!0.001), triglyceride level (PZ0.001, PZ0.002), diastolic
blood pressure (PZ0.001, P!0.001) and systolic blood
pressure (PZ0.001, PZ0.004) than controls (Table 1). No
differences were found for glucose level, cholesterol level
or smoking habits between groups. Patients in remission
had a longer hypertension duration (measured in months
since diagnosis) than active patients (PZ0.048).
No differences were found for 10-year cardiovascular
risk or vascular age when comparing patients of pituitary
or adrenal origin, either active or in remission.
White matter lesions
A second analysis was devoted to WML, which mainly
presented as small periventricular foci in patients and
controls. Patients with CS in remission had a higher degree
of WML than controls and active CS, measured with the
Scheltens scale (PZ0.001 and PZ0.035 respectively)
(Table 2 and Fig. 1). Active patients did not differ in
WML compared to controls. There were also significant
differences in the number of patients whose routine MRI
report described the presence of WML (in remission
73.9%, active 46.7%, controls 28.9%; PZ0.001).
No differences were found in the Scheltens scale when
comparing pituitary and adrenal origin in active patients
and patients in remission. However, patients in remission
who were on hydrocortisone replacement had a higher
degree of WML than patients in remission who were not
taking hydrocortisone (PZ0.023).
Neuropsychological evaluation
A third analysis was devoted to a neuropsychological
evaluation (Table 3). Patients with active CS had worse Ta
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neuropsychological performance in the memory domain
than controls (PZ0.002). No differences were found
between patients in remission and controls. Both CS
patient groups had more anxiety and depression than
controls (in remission: STAI-State PZ0.017, STAI-Trait
Q7
P!0.001, BDI-II P!0.001; active CS: STAI-State PZ0.008,
STAI-Trait P!0.001, BDI-II P!0.001).
No differences were found in cognitive function when
comparing patients of pituitary or adrenal origin (active or
in remission). In patients in remission, no cognitive
differences were found when comparing patients requir-
ing hydrocortisone or not or who had undergone radio-
therapy or not. Beck depression scores did not correlate
with cognitive function in any of the patient groups.
Brain volumes
A final analysis was devoted to brain volumes (Table 3).
Total brain volume and grey matter volume in both CS
patient groups were reduced compared to controls (total
volume: active CS PZ0.006, in remission CS PZ0.012;
grey matter: active CS PZ0.001, in remission CS
PZ0.003). There were no differences in white matter
volume between groups. No differences were found in
brain volumes when comparing pituitary and adrenal
origin in active patients and patients in remission.
Correlations
Neither the 10-year cardiovascular risk nor the vascular age
correlated with the Scheltens scale score, although both
negatively correlated with cognitive function and brain
volume in patients in remission and controls (Table 4).
Ten-year cardiovascular risk and vascular age did not
correlate with anxiety or depression scores in any group.
Figure 1
White matter lesions (the white spots seen across the MRI) in a
patient with CS in remission (left) in comparison to her matched
control (right).Q6
Table 3 Z-scores of neuropsychological test results and normalized brain volumes of patients (CS active and in remission) and
normal controls.
CS
Controls (nZ38)Active (nZ15) In remission (nZ23)
Memory (Z-scores)a K0.49G0.46* K0.05G0.76 0.22G0.66
Attention (Z-scores)b 0.05G0.76 0.01G0.55 K0.03G0.83
Executive function (Z-scores)c K0.14G0.46 0.03G0.39 0.04G0.53
Information processing speed
(Z-scores)d
K0.35G0.65 K0.21G0.86 0.15G0.72
Motor functions (Z-scores)e K0.14G1.09 K0.28G1.04 0.22G0.75
Depression (total score)f 9 (3–19)* 12 (0–23)* 2.5 (0–16)
Anxiety (total scores)g
State 20.27G10.37* 20.27G11.15* 11.36G7.56
Trait 24.93G9.86* 24.17G9.96* 13.58G7.97
Brain white matter (mm3) 382 267G64 888 386 751G40 564 408 458G31 648
Brain grey matter (mm3) 357 470G33 918* 365 632G36 581* 397 766G34 190
Total brain volume (mm3) 739 737G91 350* 752 383G73 460* 806 223G53 847
*Significant differences between patients and controls (P!0.05). All values are expressed as meanGS.D., except for depression, expressed as median and
range.
aIncludes Rey-Osterrieth Complex figure (immediate and delayed recall) and Rey Auditory Verbal-Learning Test (Rey 5 and Recognition A).
bIncludes Digit Span Forward (total score) and Continuous Performance Test II (omissions).
cIncludes Trail Making Test B (total time), FAS (total score), Animals (total score), Wisconsin Card Sorting Test (perseverative errors) and Digit Span Backwards
(total score).
dIncludes Symbol Digit Modalities Test (total score), Wisconsin Card Sorting Test (mean time) and Continuous Performance Test II (Hit Reaction Time).
eIncludes Grooved Pegboard (total time for both dominant and non-dominant hand) and Trail Making Test A (total time).
fBeck Depression Inventory-II.
gState Trait Anxiety Inventory.
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The Scheltens scale did not correlate with total brain
volume, grey matter, white matter, cognitive domains or
depression and anxiety scores, either in the CS patient
groups or in the control group (data not shown). WML
severity positively correlated with diastolic blood pressure
(rZ0.617, PZ0.002) and hypertension duration (rZ0.543,
PZ0.007) in patients in remission. In active patients these
clinical parameters did not correlate with the Scheltens
scale. The Scheltens scale did not correlate with age, years
of education, waist circumference, total cholesterol,
glucose, triglycerides, urinary free cortisol, duration of
hypercortisolism or delay to diagnosis in any group.
Discussion
Our study demonstrates that 10-year cardiovascular risk
and vascular age (as described by the Framingham heart
study (44)) are negatively associated with brain volume
and cognitive function in patients in remission of CS.
Patients in remission also have a higher degree of WML,
measured with the Scheltens scale, than controls and
patients with active CS. WML have been related to
cardiovascular risk factors in the normal population (26),
and our findings also show a relationship between WML
and hypertension in patients in remission of CS.
Ten-year cardiovascular risk correlated with both
brain volumes and cognitive function in patients in
remission of CS. This is in line with previous findings
in large samples of normal population (45, 46, 47, 48, 49).
Special attention should be paid to high 10-year
cardiovascular risk, which may imply decreased cognitive
function and reduced brain volumes. Current 10-year
cardiovascular risk has also been associated with poorer
future executive functions, in line with our results. This
association has been found in middle aged but also in
young populations (18–30 years), highlighting the
importance of controlling cardiovascular risk even at
earlier ages (48, 49).
The correlation between cardiovascular risk and both
brain volume and cognitive function was not found in
active patients with CS. This may be due to the small
sample size of the active group, whichmay have prevented
finding significant results. An analysis in a larger sample
would be needed to confirm this hypothesis. Additionally,
the effects of chronic hypercortisolism, still present in
active patients, may affect brain volume and cognitive
function more than cardiovascular risk. Hypercortisolism
itself causes cognitive dysfunctions and reduces brain
volume (10, 11, 12, 13, 14, 15, 16, 17). Possibly in the
active population, hypercortisolism plays a moreTa
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important role than cardiovascular risk on both cognitive
function and brain volume. As active patients were
affected by current hypercortisolism, it is possible that
this situation (and the role of hypercortisolism on
cognition and brain volume) may have prevented finding
associations between cardiovascular risk and both cogni-
tive function and brain volume.
We have not found any studies correlating vascular
age and both brain volumes and cognitive function. The
concept of ’vascular age’ may be a useful tool in clinical
practice for teaching patients, who may understand better
that their vascular age is higher than their current age,
rather than concepts like 10-year cardiovascular risk. In
younger individuals, knowing their ’heart-age’ has a high
emotional impact, leading to changes in their lifestyle
(50). Knowing that vascular age has been linked to poorer
cognitive function and reduced brain volumes may also
encourage patients to improve their healthy habits. In
fact, Canadian guidelines for the diagnosis and treatment
of dyslipidemia already recommend communicating
vascular age to patients to improve hypertension and
lipid control (51).
The fact that WML were increased only in cured
patients even if their vascular age was comparable to active
patients may be surprising, although it is important to
highlight that patients in remission had been exposed to
cardiovascular risk for a longer time. In fact, the algorithm
for 10-year cardiovascular risk and vascular age only
includes current risk factors, not a measure of time
exposed to cardiovascular risk. The correlations between
WML and length of hypertension exposure are in line with
this hypothesis.
According to some authors, the presence of WML has
been reported in 11–21% of 64-year-old patients. The
presence of WML lesions increases with time, and the
percentage of older patients with WML at the age of 82
increases to 94% (23). Taking into account the number of
patients whose routine MRI reports described the presence
of WML (in remission 73.9%, mean age 44.3G9.3; active
46.7%, mean age 42.9G10.6), it seems that the WML
presence in our patient population is higher than
expected, maybe in line with the brain-aging effect
suggested by some authors in Cushing’s syndrome (52).
Our results also showed a relationship between
hypertension and WML in patients in remission. Hyper-
tension is a known strong predictor for WML (53, 54).
More specifically, the severity of hypertension and bad
control in treated hypertensive patients has been associ-
ated with the presence of WML (55, 56, 57). These lesions
may worsen over time. In uncontrolled hypertension,
progression is higher in untreated rather than in treated
patients, suggesting that hypertension treatment could
reduce WML progression (58).
The duration of hypertension has also been associated
with WML in the normal elderly population (57). In fact,
apart from current hypertension, hypertension estab-
lished 5 or 20 years before has also been associated to
current WML in the old age (57, 59). This is in line with
our results and could explain the differences in WML
between active patients and patients in remission. The
latter have longer hypertension exposure than active CS,
andWML severity positively correlated with hypertension
duration in patients in remission. These data indicate that
the cause of WML may not be CS itself but rather long-
term hypertension exposure caused by CS.
Regarding cognitive function, it is important to
highlight that all Z-scores were within one S.D. both in
active and treated CS, implying no severe impairments
in cognition. These data are in line with previous literature
in patients in remission in which all Z-scores were also
within one S.D., even if significant differences in cognition
between patients in remission and both normal controls
and non-functioning adenomas were found (3). Regarding
active patients, according to the literature, greater deficits
may be expected (16, 60). Furthermore, significant
differences with controls were only found for the memory
domain. The fact that most of the active patients were on a
cortisol-lowering medication may have prevented finding
greater impairment. We had no data on cognitive
performance before suffering CS; nevertheless, most of
the patients complained about having a poor cognitive
performance, mainly memory problems, in comparison to
their prior capacities.
WML have been associated with reduced brain
volumes and impaired cognitive function (23, 25, 61),
although this was not the case in our study. The Scheltens
scale scores did not correlate with cognitive function or
brain volume in patients with CS. Most of the literature
studies on WML have been performed in older popu-
lations, where cognitive decline and brain atrophy are
more pronounced. It is possible that the younger age of
our patients may have prevented finding any significant
correlations; however, a higher degree of WML may be
related to poorer cognitive performance and reduced brain
volumes when they reach an older age, which, given the
cross-sectional nature of this study, could not be
evaluated.
In fact, even if we did not find correlations between
WML and cognitive function, WML are known to
predispose to dementia, stroke and cognitive decline in
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old age (23, 25). This is a key finding with important
clinical implications as it implies that this patient cohort
may be cognitively compromised in the future. Never-
theless, control of hypertension may prevent progression
of WML (56, 57) and reduce the risk of developing
dementia and cognitive decline (62, 63). Thus, adequate
control of hypertension would appear to be mandatory
both in patients in remission, usually exposed to
hypertension for a long time and with a higher degree of
WML, and in active patients to prevent WML progression
at an early stage. Patients should be informed on the risks
of inadequate control of hypertension and on healthy
habits to control hypertension. Education on drugs that
may worsen hypertension such as non-steroidal anti-
inflammatory drugs (64, 65) is worth recommending.
Patients in remission taking hydrocortisone had a
higher degree of WML than patients who were not on
hydrocortisone replacement. This would suggest limiting
the use of hydrocortisone as much as possible; in practice,
it may be difficult for patients to differentiate symptoms
related to adrenal insufficiency from other causes. This
may lead to taking extra doses of hydrocortisone, which
may worsen hypertension (66). They should be encour-
aged to check their blood pressure regularly and to not
’routinely’ take extra hydrocortisone doses when suffering
from common complaints like tiredness or headache.
This study has several limitations. The small sample
size is difficult to avoid in rare diseases, such as CS. It may
have led to a low statistical power and possibly prevented
the identification of significant findings, mainly in the
active patients. Therefore, confirmatory analysis in larger
samples of active patients would be needed, for instance,
to check if there is a relationship between cardiovascular
risk and both cognitive function and brain volume.
Another limitation is the heterogeneity of the sample,
because different causes of CS have been included, at
different stages of the disease. Additionally, for non-
parametric data in which differences were identified, no
post hoc correction was performed. Longitudinal studies
would be necessary to analyse WML progression in active
patients and also to investigate the role of hypertension
control in both active and in remission CS to prevent
WML worsening.
In conclusion, our study describes negative corre-
lations between cardiovascular risk and both brain volume
and cognitive function in CS patients in remission.
Moreover, it describes a high prevalence of WML in
these patients, probably mediated by hypertension. These
findings emphasize the importance of controlling
cardiovascular risk factors to prevent brain damage in
patients who have been diagnosed and treated for CS.
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